More positive results from Biogen's Phase III Spinraza study

13 January 2017

American biotech company Biogen (Nasdaq: BIIB) has released more positive results from a Phase III trial into its musculoskeletal product candidate Spinraza (nusinersen).

Spinraza is designed to treat spinal muscular atrophy (SMA), a condition which causes severe and progressive muscular atrophy and weakness. The incidence rate for SMA is about 1 in 10,000 births, and there are about 9,000 patients in the USA with the condition.

“The study demonstrated that a significantly greater number of infants treated with Spinraza survived and did not require permanent ventilation. These data further underscore the impact Spinraza may have on individuals living with this devastating disease,” said Wildon Farwell, senior medical director at Biogen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK